Article

Glaucoma valve implantation viable method for IOP control in PKP eyes

Implantation of a proprietary glaucoma valve (Ahmed Glaucoma Valve, New World Medical) is an effective method for managing refractory glaucoma in eyes undergoing penetrating keratoplasty (PKP) or with an existing corneal graft, according to results of a retrospective review.

Key Points

Fort Lauderdale, FL-Implantation of a proprietary glaucoma valve (Ahmed Glaucoma Valve, New World Medical) is an effective method for managing refractory glaucoma in eyes undergoing penetrating keratoplasty (PKP) or with an existing corneal graft, reported researchers from the University of Nottingham here at the annual meeting of the Association for Research in Vision and Ophthalmology.

"An aqueous drainage device, such as the [glaucoma] valve, may especially be considered to manage glaucoma in eyes undergoing PKP if traditional filtering surgery with adjunctive antimetabolite is likely to be unsuccessful or has failed or to manage refractory glaucoma associated with PKP," said Arun Lakshmanan, MD, affiliated with the Department of Ophthalmology and Visual Sciences, University of Nottingham, United Kingdom. Harminder S. Dua, MD, professor of ophthalmology, was the senior author of the project.

"In our retrospective review of such patients with a mean follow-up of 32 months, we found the overall success rate of valve implantation was 65%. This outcome was comparable to other published results," Dr. Lakshmanan said.

At last follow-up, BCVA ranged from light perception to 6/9. IOP was significantly reduced from 31 mm Hg at baseline to 15.7 mm Hg, and that benefit was accompanied by a significant reduction in glaucoma medication use from a mean of three medications per patient to 1.78.

Surgical success was defined as IOP <22 mm Hg and >5 mm Hg at the past two visits with or without glaucoma medications, along with BCVA of light perception or better, absence of any devastating complications (e.g., choroidal hemorrhage), and without any additional glaucoma surgery or valve removal. The 11 eyes that achieved surgical success included four of seven eyes (57%) in the group that underwent valve implantation after or simultaneously with PKP and seven of 10 eyes (70%) that had valve implantation for glaucoma developing after PKP. The rate of surgical success was not significantly different between the two groups, and a significant reduction from baseline IOP and in glaucoma medication usage was achieved in both groups.

Complications occurred intraoperatively in four eyes, including conjunctival buttonholing in three eyes and vitreous hemorrhage in one eye. The most common postoperative complication was valve occlusion (five eyes, 29.4%). Also, tube exposure with leakage occurred in two eyes (11.8%).

"Good control of postoperative inflammation may help to reduce the risk of valve occlusion," Dr. Lakshmanan said.

Among the six eyes in which surgery was considered a failure, three underwent valve replacement, one required glaucoma valve revision, one had uncontrolled IOP, and one eye became phthisical.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.